GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$0.66
+0.07 (+11.58%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| EPS | — | — | — |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| Rev Growth | +12.1% | -7.4% | -2.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.54M | 1.37M | 1.48M |
| Total Equity | 995.4K | 1.02M | 1.05M |
| D/E Ratio | 1.54 | 1.34 | 1.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |